Erratum to: Cancer Chemother Pharmacol DOI 10.1007/s00280-014-2609-3
Unfortunately, a co-author’s name was not listed in the original publication. The missing author’s name is given below:
H.-J. Lenz,
University of Southern California, Los Angeles, CA, USA
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s00280-014-2609-3.
Rights and permissions
About this article
Cite this article
Hochster, H.S., Uboha, N., Messersmith, W. et al. Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol 75, 25 (2015). https://doi.org/10.1007/s00280-014-2625-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-014-2625-3